FEBRI KNOCK

Main information

  • Trade name:
  • FEBRI KNOCK 100ML
  • Composition:
  • 100ML
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FEBRI KNOCK 100ML
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

4-6-2018

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer.

FDA - U.S. Food and Drug Administration

There are no news related to this product.